# Granza Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/granza-bio

- Industry: Healthcare Specialists
- Headquarters: London, UK
- Website: www.granzabio.com
- Total disclosed funding: $7.1M
- Latest round: Seed (Jun 30, 2024)
- Investors on record: 9

## About

Established in 2023 and based in London, UK, Granza Bio Limited operates as a drug development company that offers cancer therapeutics and develops attack particles that target and destroy cancer cells while leaving healthy cells unharmed. The company was founded by its CEO, Ashwin Nandakumar, and CSO, Ashwin Jainarayanan.

Granza Bio develops personalized and targeted cancer treatments. The firm offers cancer-targeting attack particles, a new class of cancer therapeutics engineered from the body's immune system. The company uses attack particles to target and kill cancer cells while leaving healthy cells unharmed. The firm’s attack particles fight various cancers, including brain, ovarian, lung, and skin cancers.

## Funding rounds

- Seed, Jun 30, 2024, $7.1M — Felicis Ventures, Y Combinator, Refactor Capital, Zeno Ventures, Pioneer Fund, Oxonian Ventures, Metaplanet Holdings, North South Ventures, Ritual Capital
- Seed, Mar 18, 2024 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Zeno Ventures (https://capitalatlas.ai/funds/zeno-ventures) — Seed
- Oxonian Ventures (https://capitalatlas.ai/funds/oxonian-ventures) — Seed
- Metaplanet Holdings (https://capitalatlas.ai/funds/metaplanet-holdings) — Seed
- North South Ventures (https://capitalatlas.ai/funds/north-south-ventures) — Seed
- Ritual Capital (https://capitalatlas.ai/funds/ritual-capital) — Seed